PRPH earnings analysis
What we found in PRPH's 10-Q: the parts that mattered, the offsets in the same document, and what the company said about what comes next.
Our reading of the filing · Free to read, no account needed
The provided 10-Q excerpt does not include the income statement, balance sheet, cash-flow statement, or segment disclosures, so current-period revenue, margins, EPS, cash flow, and working-capital metrics cannot be reported. Liquidity is the principal concern: as of June 30, 2026, the Company reported approximately $5.7 million of debt against approximately $20,000 of cash and warned that it may need asset sales, debt restructuring, or additional equity capital. Sentiment is bearish due to ineffective disclosure controls, pending litigation, consumer-service issues, and newly detailed risks associated with a potential crypto treasury strategy.
The parts that mattered.
Pulled out of the filing itself, with the figures the company reported.
- Government Declines False Claims Act Intervention
- The Department of Justice and relevant state authorities declined to intervene in the False Claims Act matter involving the Company’s diagnostic subsidiaries. The case remains pending, but no ongoing government investigation is known to the Company.
- Limited Interest-Rate Exposure
- Management states that a 1 percentage-point change in short-term interest rates would not materially affect future earnings, fair value, or cash flows related to cash equivalents and interest-earning marketable securities.
- Market-Risk Exposure Unchanged
- The Company reports no material changes in market-risk exposures since December 31, 2025, and states that its operations are not subject to material foreign-currency fluctuations.
And the other side of it.
The offsets in the same document — the things a summary that only listed the good news would have left out.
- Severe Liquidity and Debt Mismatch
- As of June 30, 2026, the Company had approximately $5.7 million of outstanding indebtedness, net of discounts, but only approximately $20,000 in cash and cash equivalents. The filing warns that insufficient operating cash flow could require asset sales, debt restructuring, or potentially highly dilutive equity capital.
- Ineffective Disclosure Controls
- Management concluded that disclosure controls and procedures were ineffective at the reasonable-assurance level as of June 30, 2026. Although no material changes to internal control over financial reporting were identified during the quarter, ineffective disclosure controls increase reporting and governance risk.
- Potential Crypto Treasury Exposure
- The filing newly details a potential crypto treasury strategy, including risks of extreme volatility, illiquidity, theft, regulatory changes, and increased stock-price volatility. The Company warns that digital assets could be irretrievably lost following a cyberattack, systems failure, or human error.
- Consumer Complaints and Reputation Risk
- DNA Complete is not BBB-rated, while Nebula Genomics has a current BBB rating of “B.” The companies reportedly fell behind in sequencing after a laboratory change, and recurring complaints about fulfillment, billing, or results access could reduce demand and increase regulatory or liability exposure.
- Nebula Genetic-Privacy Litigation
- A putative class action filed in October 2024 alleges that Nebula improperly shared customers’ genetic information without written consent under Illinois’s Genetic Information Privacy Act. The complaint remains at the pleading stage, and potential liability is not reasonably estimable.
- Convertible-Note Default Arbitration
- The Company is involved in arbitration commenced by Turnpoint Capital concerning a senior secured convertible note issued in July 2025. Turnpoint alleges events of default and seeks monetary damages, but the Company cannot estimate the potential loss, recovery, or timing.
What they said about what is next.
The provided 10-Q excerpt contains no quantitative revenue or EPS guidance. Management's outlook is not quantified; the filing notes that the Company may need to sell assets, restructure debt, or obtain additional equity capital if operating cash flow is insufficient.
The filing reads worse than the one before it.
What came before.
- 10-Q · July 9, 2026
- ProPhase Labs, Inc. reported a revenue of $1.2 million for Q1 2026, a decrease of 14.3% compared to $1.4 million in Q1 2025, driven by lower supplement sales. Gross margin fell to 25.3% from 36.8% year-over-year, while…
- 10-Q · July 7, 2026
- ProPhase Labs, Inc.'s Q1 2026 results show a steep decline in revenue to $0.5 million from $1.4 million in the prior year, primarily due to falling supplement sales. The company remains under significant financial…
- 10-Q · June 30, 2026
- ProPhase Labs, Inc. reported a significant decrease in net revenues of 64.3% to $0.5 million for Q1 2026 compared to $1.4 million in Q1 2025. This decline is attributed primarily to a decrease in revenue from supplement…
- 10-K · June 1, 2026
- ProPhase Labs, Inc. reported a substantial decrease in revenue, with net revenue declining by 35.8% to $4.3 million in 2025 from $6.8 million in 2024, coupled with significant operational losses attributed to its…
This is our reading of a public filing, not the filing. Read the original on SEC.gov · Educational only. Nothing here is investment advice.
Read the next one first.
We read every filing PRPH makes the day it lands, and put it next to what the options market did about it. Members get both, and an alert when a filing arrives.
Cancel anytime · Month to month · Switch tiers whenever